$5.70
Today
as of Jul 22, 16:40 ET
Last 30 days
Recent Press Releases & News
Verrica Pharmaceuticals Signs Distribution Deal With Medomie for Molluscum Treatment
Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel
Verrica Pharmaceuticals' Doses First US Patient in Phase 3 Trial Evaluating Ycanth to Treat Common Warts
Overview
52-week range
$3.28
$9.82
37% of range
Avg surprise (last 3)
+52.1%
Avg reaction (last 2)
+2.7%
50% positive
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue May 12, 2026 | Mar/2026 | $-0.45 | $-0.60 | +25.0% | -350.0% | -3.4% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.03 | — | — | — | — | financials |
| Tue Aug 12, 2025 | Jun/2025 | $0.02 | $-0.70 | +102.9% | — | — | earnings |
| Tue May 13, 2025 | Mar/2025 | $-0.10 | $-0.14 | +28.6% | — | +8.7% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-4.88 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-3.70 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.44 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.54 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.24 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Tue Aug 11, 2026 | Jun/2026 | OTHER | — | $0.02 |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5M | — | $14M | — | $3M | — | $-2M | — |
| Cost of revenue | — | — | — | — | $700,000 | — | $400,000 | $700,000 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-10M | — | $2M | $2M | $-8M | — | $-21M | $-15M |
| Net income | $-10M | — | $-274,000 | $204,000 | $-10M | — | $-23M | $-17M |
| EPS (diluted) | $-0.45 | — | $-0.03 | $0.02 | $-1.03 | — | $-4.88 | $-3.70 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $21M | $30M | $21M | $15M | $30M | $46M | $23M | $32M |
| Inventory | $2M | $2M | $2M | $3M | $2M | $2M | $3M | $3M |
| Total current assets | $34M | $43M | $36M | $37M | $39M | $51M | $28M | $47M |
| Total assets | $39M | $47M | $41M | $39M | $42M | $54M | $33M | $52M |
| Long-term debt | — | — | $22M | $25M | $28M | $31M | $43M | $43M |
| Total liabilities | $23M | $22M | $58M | $57M | $61M | $64M | $67M | $65M |
| Total equity | $16M | $25M | $-17M | $-17M | $-19M | $-10M | $-34M | $-13M |
Implied volatility — last 90 days
No IV snapshots yet for VRCA.
IV is captured twice daily (9:15 AM & 4:30 PM ET) for tickers with upcoming earnings. Comes online automatically once the next options refresh runs.